

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 12

Complete If Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	583	2004/0265919 A1	12-30-2004	Vanderschlele et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	576	6,818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schenk et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750,324	06-15-2004	Schenk et al.	
	573	6,743,427	06-01-2004	Schenk	
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	415	2003/0166558 A1	09-04-2003	Frangione et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	360	2003/0073655 A1	04-17-2003	Chain	
	370	2003/0068325 A1	04-10-2003	Wang	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	378	2002/0197258 A1	12-26-2002	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Geftter et al.	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	416	6,303,567 B1	10-16-2001	Findeis et al.	
381	2001/0021769 A1	09-13-2001	Prusiner		

Examiner
SignatureDate
Considered

9/29/05

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60555940



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete If Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/724,575</td> </tr> <tr> <td>Filing Date</td> <td>November 28, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Schenk</td> </tr> <tr> <td>Art Unit</td> <td>1649</td> </tr> <tr> <td>Examiner Name</td> <td>Kolker, D. E.</td> </tr> <tr> <td>Attorney Docket Number</td> <td>15270J-005912US</td> </tr> </table>		Application Number	09/724,575	Filing Date	November 28, 2000	First Named Inventor	Schenk	Art Unit	1649	Examiner Name	Kolker, D. E.	Attorney Docket Number	15270J-005912US
Application Number	09/724,575														
Filing Date	November 28, 2000														
First Named Inventor	Schenk														
Art Unit	1649														
Examiner Name	Kolker, D. E.														
Attorney Docket Number	15270J-005912US														
Sheet	2	of	12												

DK	401	6,284,533 B1	09-04-2001	Thomas	
	516	6,261,569	07-17-2001	Comis et al.	
	452	6,218,506 B1	04-17-2001	Krafft et al.	
	510	6,022,859	02-08-2000	Klessling, et al.	
	417	5,985,242	11-16-1999	Findels et al.	
	512	5,891,991	04-06-1999	Wasco et al.	
	445	5,854,215	12-29-1998	Findels et al.	
	382	5,846,533	12-08-1998	Prusiner	
	446	5,817,626	10-06-1998	Findels et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	380	5,750,361	05-12-1998	Prusiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	515	5,652,334	07-29-1997	Roberts	
	584	5,589,154	12-31-1996	Anderson	
	574	5,576,184	11-19-1996	Better et al.	
	513	5,514,548	05-07-1996	Krebber et al.	
	514	5,470,951	11-28-1995	Roberts	
	403	5,464,823	11-07-1995	Lehrer et al.	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5,096,706	03-17-1992	Flint	
	570	4,912,206	03-27-1990	Goldgaber et al.	
✓	402	4,713,366	12-15-1987	Stevens	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
DK	533	AU	707083		07-01-1999			
	523	EP	752 886	B1	01-28-1998			
	587	JP	7-165799	A	06-27-1995			abst. only
	585	WO	04/080419	A2	09-23-2004			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/13172	A2, A3	02-12-2004			
	441	WO	03/104437	A2	12-18-2003			

Examiner Signature		Date Considered	9/27/05
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60555940



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 12

Complete If Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

DK	586	WO	03/077858	A2, A3	09-25-2003			
	443	WO	03/74081	A1	09-12-2003			
	447	WO	03/51374	A2	06-26-2003			
	433	WO	03/20212	A2	03-13-2003			
	458	WO	02/60481	A1	08-08-2002			
	457	WO	02/46237	A1	06-13-2002			
	557	WO	02/88307	A2	11-07-2002			
	556	WO	02/88306	A2	11-07-2002			
	456	WO	02/21141	A2	03-14-2002			
	450	WO	01/18169	A3	03-15-2001			
	455	WO	01/10900	A2	02-15-2001			
	529	WO	00/68263	A2	11-16-2000			
	519	WO	00/26238	A2	05-11-2000			
	555	WO	00/23082	A1	04-27-2000			
	522	WO	00/20027	A2	04-13-2000			
	526	WO	99/06587	A2	02-11-1999			
	454	WO	98/33815	A1	08-06-1998			
	520	WO	98/22120	A1	05-28-1998			
	530	WO	98/08868	A1	03-05-1998			
	521	WO	98/05350	A1	02-12-1998			
	525	WO	98/02462	A1	01-22-1998			
	527	WO	97/32017	A1	09-04-1997			
	383	WO	97/10505	A1	03-20-1997			
	528	WO	97/08320	A1	03-06-1997			
	532	WO	96/37621	A2	11-28-1996			
	518	WO	95/23166	A1	08-31-1995			
	531	WO	95/08999	A1	04-06-1995			
	524	WO	95/05393	A2	02-23-1995			
✓	517	WO	94/05311	A1	03-17-1994			

Examiner
Signature

Daniel E. Kolker


Date
Considered

9/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60555940



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4

of 12

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).	
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β -Protein (A β) Deposits With Numerous A β -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).	
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).	
	448	ANDREW et al., <u>Current Protocols in Immunology</u> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).	
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <u>DNA and Cell Biology</u> , 20(11):737-744 (2001).	
	485	BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <u>Nature Medicine</u> , 7(3):369-372 (2001).	
	504	BALBACH et al., "Amyloid fibril formation by A β ₁₈₋₂₂ , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <u>Biochemistry</u> , 39:13748-13759 (2000).	
	550	BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).	
	561	BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <u>Renal Failure</u> , 15(3):365-371 (1993).	
	404	BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
	558	BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <u>J. Biol. Chem.</u> , 268(23):26279-26285 (1993).	
✓	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996).	

Examiner
Signature

Daniel E. Kolker

Date
Considered

9/27/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 5

of 12

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

DK	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000).
	420	BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999).
	461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <u>J. Biol. Chem.</u> , 267:546-555 (1992).
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabete & Metabolisme (Paris)</u> , 21:3-25 (1995).
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <u>J. Biol. Chem.</u> , 276(24):21562-70 (2001).
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).
	509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000).
	462	CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992).
	541	CRIBBS et al., "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997).
	412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).
	469	DEMATTO et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 98(15):8850-8855 (2001).
	493	DEMATTO et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-236 (2002).
	486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).
	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996).
✓	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?," <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).

Examiner
SignatureDate
Considered

9/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 6 of 12	Attorney Docket Number	15270J-005912US	

DK	422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).	
	407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996).	
	475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998).	
	501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).	
	539	FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6791-6800 (1999).	
	464	FLOOD et al., "An amyloid β -Protein fragment, A β [12-28J, equipotently impairs post-training memory processing when injected into different limbic system structures," <u>Brain Res.</u> , 663(2):271-276 (1994).	
	538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).	
	423	FONSECA et al., "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age," <u>Experimental Neurology</u> , 157(2):277-288 (1999).	
	386	FRAUTSCHY et al., "Effects of injected Alzheimer β -amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991).	
	565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	364	FURLAN et al., "Vaccination with amyloid- β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem. J.</u> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <u>J Neurosci.</u> , 16 (19):6021-6037 (1996).	
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-65 (1995).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology</i> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465 (2000).	

Examiner Signature	<i>Timothy E. Kolker</i>	Date Considered	9/27/05
--------------------	--------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 7 of 12	Attorney Docket Number	15270J-005912US	

503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <u>Biochem. and Biophys. Res. Commun.</u> , 147(2):854-862 (1987).
487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?," <u>Nature Neuroscience</u> , 4(9):859-860 (2001).
476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> 160:1029-1035 (1998).
559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma", <u>Eur. J. Immunol.</u> 9:657-659 (1979).
473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> 218:149-163 (1991).
471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <u>J. Mol. Biol.</u> 228:460-473 (1992).
534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).
413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).
546	IRIZARRY et al., "A β Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).
560	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).
374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51 (1995).
449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A β ₄₂ deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94:1550-1555 (1997).
371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochem. Biophys. Res. Comm.</u> , 220:710-718 (1996).
547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <u>J. Mol. Biol.</u> , 287:781-796 (1999).
434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).

Examiner Signature	<i>James E. Kolker</i>	Date Considered	9/27/05
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
		Attorney Docket Number	15270J-005912US
Sheet	8	of	12

DK	554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <u>Protein Engineering</u> , 4(7):773-783 (1991).	
I	488	KLEIN et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?," <u>Trends in Neurosciences</u> , 24(4):219-224 (2001).	
	494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002).	
	465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. & Biophys. Res. Comm.</u> , 205:1164-1171 (1994).	
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).	
	478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999).	
	477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998).	
	489	LAMBERT et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 79:595-605 (2001).	
	490	LEE et al., "A β immunization: Moving A β peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001).	
	553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).	
	551	LEVERONE et al., "A β 1-15 is less immunogenic than A β 1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting," <u>Vaccine</u> , 21:2197-2206 (2003).	
	459	LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983).	
	481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <u>American Neurological Assoc.</u> , 48:553-554 (2000).	
	499	LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-862 (1999).	
	502	MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <u>Brain Pathology</u> , 6:147-162 (1996).	
✓	408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	

Examiner Signature	<i>Janet E. Kolker</i>	Date Considered	9/27/05
--------------------	------------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 9 of 12	Attorney Docket Number	15270J-005912US	

DK	545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).	
	479	MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999).	
	367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).	
	439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	
	482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <u>J. Am. Med. Assoc.</u> , 283:1571 (2000).	
	425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).	
	568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimmers," <u>PNAS</u> , 82:4592-4596 (1985).	
	409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	
	406	PAN et al., "Antibodies to β -Amyloid Decrease the Blood-to-Brain Transfer of β -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).	
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856	
	437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only	
	491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001).	
	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).	
✓	460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989).	

Examiner Signature	<i>David E. Kolker</i>	Date Considered	9/27/05
--------------------	------------------------	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk		
		Art Unit	1649		
		Examiner Name	Kolker, D. E.		
Sheet	10	of	12	Attorney Docket Number	15270J-005912US

DK	497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998).	
I	414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	
	466	SCHWARZMAN et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994).	
	536	SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999).	
	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).	
	552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).	
	505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994).	
	426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).	
	438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only	
	427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).	
	411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).	
	549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	
	508	SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <u>J. Biol. Chem.</u> , 270(7):3063-3067 (1995).	
	369	SPOONER et al., "The generation and characterization of potentially therapeutic A β antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002).	
✓	435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990).	

Examiner Signature	<i>James E. Kolker</i>	Date Considered	9/27/05
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11

of 12

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

OK	496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993).	
I	361	SU et al., "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).	
	498	SUO et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998).	
	467	TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994).	
	399	TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994).	
	472	TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996).	
	500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).	
	537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <u>J. Biol Chem.</u> , 272(19):12601-12605 (1997).	
	492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <u>Neurosci. Lett.</u> , 307:101-104 (2001).	
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A β 40 and A β 42: immunohistochemical evidence for amyloid β protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995).	
	535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998).	
	428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997).	
	410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).	
	569	VERSHIGORA A. E. OSHCHAYA IMMYNOLOGIYA, pages 35, 229-231 and 152-153.	
	480	WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <u>Experimental Neurology</u> , 158:328-337 (1999).	
✓	495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <u>Brain Research</u> , 924:133-140 (2002).	

Examiner
SignatureDate
Considered

9/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60555940

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet 12 of 12	Attorney Docket Number	15270J-005912US	

DK	387	WELDON et al., "Neurotoxicity of A β Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996).	
	429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8509-8517 (1990).	
	474	WINTER et al., "Humanized antibodies" <u>Immunology Today</u> , 14(6):243-246 (1996).	
	468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <u>Neurobiol. Aging</u> , 15(2):143-52 (1994).	
	506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β /A4" <u>Biochemistry</u> , 34:724-730 (1995).	
	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970).	
	507	XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997).	
	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
	483	ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000).	
✓	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.	

Examiner Signature		Date Considered	9/27/05
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60555940